Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Mtor Signaling Pathway and Cancer

How is the AKT/mTOR Pathway Involved in Cell Migration and Invasion?

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Advance in Research on the Relationship Between Mtor Signaling Pathway and Tumors

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Emerging Role of MicroRNAs in Mtor Signaling

mTOR Signaling in Growth Control and Disease

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Progress in mTOR study

Targeting Mtor Network in Colorectal Cancer Therapy

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

Mtor Signaling in Stem and Progenitor Cells

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Targeting PI3K/Akt/mTOR Signaling in Cancer

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research